Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01314014 · ClinicalTrials.gov registry record · Phase 2

Imexon for Relapsed Follicular and Aggressive Lymphomas

A Phase 2 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, sponsored by University of Rochester.

Completed
Registry status
Phase 2
Development phase
22
Enrollment target
2
Study locations

NCT01314014 is a Phase 2 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma that has completed, run by University of Rochester. The registered enrollment target is 22 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01314014, a Phase 2 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
Phase 2
Development phase
22 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine whether Amplimexon (imexon for injection) is effective in the treatment of indolent and aggressive lymphomas that have progressed after treatment with standard therapies.

Conditions Studied

Diffuse Large B Cell Lymphoma Mantle Cell Lymphoma Follicular Lymphoma Small Lymphocytic Lymphoma Marginal Zone Lymphoma Lymphoplasmacytic Lymphoma Burkitt's Lymphoma

Interventions

  • DRUG Imexon

Study Locations (2)

Arizona

  • Arizona Cancer Center, University of Arizona - Tucson

New York

  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2011-05
Est. Completion 2014-08
Phase Phase 2

Sponsor

University of Rochester

636 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01314014

The ClinicalTrials.gov registry entry for NCT01314014 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Imexon is the first listed.

NCT01314014 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, New York.

Frequently Asked Questions

What is clinical trial NCT01314014 about?

NCT01314014 is a clinical study titled "Imexon for Relapsed Follicular and Aggressive Lymphomas". The purpose of this study is to determine whether Amplimexon (imexon for injection) is effective in the treatment of indolent and aggressive lymphomas that have progressed after treatment with standard therapies.

What is the current status of trial NCT01314014?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2011-05. Estimated completion is 2014-08.

What conditions does trial NCT01314014 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma.

What interventions are being tested in trial NCT01314014?

The interventions under investigation include: Imexon (DRUG).

Who is sponsoring clinical trial NCT01314014?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01314014 being conducted?

This trial has 2 study locations across Arizona, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Mantle Cell Lymphoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.